Literature DB >> 14556257

Modifications and substitutions of the RNA extraction module in the ViroSeq HIV-1 genotyping system version 2: effects on sensitivity and complexity of the assay.

Martin Stürmer1, Annemarie Berger, Hans-Wilhelm Doerr.   

Abstract

Genotypic testing for HIV-1 resistance to anti-retroviral drugs has become accepted widely as a routine method to guide anti-retroviral therapy. However, implementation into routine high-throughput laboratory diagnosis is difficult due to the complexity of the assay. A commercially available assay is the ViroSeq HIV-1 Genotyping System (Applied Biosystems, Weiterstadt, Germany). We modified and substituted the RNA extraction module to optimize the proportion of samples amplified successfully as follows: 1 ml plasma was concentrated by ultracentrifugation and extracted according to the manufacturer's instructions (Kit), by substituting the lysis buffer (Roche, Roche Diagnostics GmbH, Mannheim, Germany), and by using the QIAamp Viral RNA Kit (Qiagen GmbH, Hilden, Germany) with elution volumes of 60 (Q60) or 50 micro l (Q50). Overall Q50 showed a higher success rate (97%) than the other extraction modules used (range 88-91%). In samples with a viral load range of 1,000-4,999 copies/ml, Q50 was superior (95 vs. 65% to 83%), while in samples with a viral load range of 5,000-9,999 copies/ml or those with 10,000 or more copies/ml, the success rate of the extraction procedures showed no significant differences. In 18 samples, which were negative using the Kit or Roche extraction, Q60 resulted in 7/18 positive results; in addition the Q50 was successful in amplifying 7/10 of the Q60 negative samples. When investigating samples with a measurable viral load of less than 1,000 copies/ml or lower, Q50 had the highest success rate with 80% compared to the other procedures (33-63%). A statistically significant new cut-off could be defined for Q50 at a value of 250 copies/ml. The results showed clearly that the ViroSeq System is suitable for analyzing the HIV-1 genotype over a wide range of viral loads but could be improved significantly when substituting the RNA extraction module with Q50 without using a nested PCR protocol. This is of great importance as it avoids further time- and cost-intensive steps. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14556257     DOI: 10.1002/jmv.10527

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  Long-Range HIV Genotyping Using Viral RNA and Proviral DNA for Analysis of HIV Drug Resistance and HIV Clustering.

Authors:  Vlad Novitsky; Melissa Zahralban-Steele; Mary Fran McLane; Sikhulile Moyo; Erik van Widenfelt; Simani Gaseitsiwe; Joseph Makhema; M Essex
Journal:  J Clin Microbiol       Date:  2015-06-03       Impact factor: 5.948

2.  Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes.

Authors:  Martin Stürmer; Christoph Stephan; Peter Gute; Gaby Knecht; Markus Bickel; Hans-Reinhard Brodt; Hans W Doerr; Lutz Gürtler; Pierre Lecocq; Margriet van Houtte
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

3.  Importance of Viral Sequence Length and Number of Variable and Informative Sites in Analysis of HIV Clustering.

Authors:  Vlad Novitsky; Sikhulile Moyo; Quanhong Lei; Victor DeGruttola; M Essex
Journal:  AIDS Res Hum Retroviruses       Date:  2015-02-06       Impact factor: 2.205

4.  Improved virological and immunological efficacy of resistance-guided switch in antiretroviral therapy: a Frankfurt HIV cohort analysis.

Authors:  T Wolf; B Fuß; P Khaykin; A Berger; G Knecht; P Gute; H R Brodt; S Goepel; M Bickel; M Stuermer; C Stephan
Journal:  Med Microbiol Immunol       Date:  2014-08-23       Impact factor: 3.402

5.  Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1.

Authors:  Jörn Lötsch; Sebastian Harder; Martin Stürmer; Hans-Wilhelm Doerr; Gerd Geisslinger; Schlomo Staszewski; Nils von Hentig
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

6.  Prevalence of K65R in patients treated with tenofovir disoproxil fumarate: recommendations based on the Frankfurt HIV Cohort Study Resistance Database (FHCS-RD).

Authors:  Claudia Reinheimer; Anna Wesner; Oliver T Keppler; Hans Wilhelm Doerr; Eva Herrmann; Martin Stürmer; Christoph Stephan
Journal:  Med Microbiol Immunol       Date:  2016-01-08       Impact factor: 3.402

7.  Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy.

Authors:  Christoph Stephan; Valentin Bartha; Eva Herrmann; Nils von Hentig; Pavel Khaykin; Gaby Knecht; Peter Gute; Hans-Reinhard Brodt; Martin Stürmer; Annemarie Berger; Markus Bickel
Journal:  Med Microbiol Immunol       Date:  2012-09-15       Impact factor: 3.402

8.  Mutations in the C-terminal region of the HIV-1 reverse transcriptase and their correlation with drug resistance associated mutations and antiviral treatment.

Authors:  I Michels; S Staszewski; L Gürtler; G Nisius; A Müller; L Locher; H-W Doerr; Martin Stürmer
Journal:  Eur J Med Res       Date:  2010-10-25       Impact factor: 2.175

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.